The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis.

The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis.

Blog Article

BackgroundThe role of surgery in treating small cell lung cancer (SCLC) remains controversial.This Lift Top Desk meta-analysis aims to determine whether surgical-based treatment improves survival in comparison to radiotherapy, chemotherapy, and chemoradiotherapy for stage I to III SCLC.MethodsPubMed, PubMed Central, EMBASE, Web of Science, and Cochrane Library were searched for relevant articles.

The main outcome were overall survival (OS), reported as hazard ratios (HRs), and 95% confidence intervals (CIs).ResultsTwo randomized control trials (RCTs) and 13 retrospective studies that included a total of 41,483 patients were eligible.Surgical resection significantly improved OS when compared to non-surgical treatment in retrospective studies (HR = 0.

56, 95% CI: 0.49-0.64, P ConclusionsSurgery-based multi-modality treatment appears to be associated with a favorable Dresser and Changer Top survival advantage in stage I and selected stage II to III SCLC.

Lobectomy is likely to provide superior OS when compared to sublobar resection.Further prospective RCTs are needed to confirm these findings.